Hematology Analyzer Patents: Who Leads, Where the Gaps Are 2026
Hematology Analyzer Patents: Filing Concentration and Where Claim Space Is Still Open
Top-heavy field. the top 5 assignees hold 55.0% of all 191 records in scope, and the top 10 hold 82.7% — this is a field with a short list of gatekeepers, not a fragmented one. Filings rose from a single record in 2017 to a peak of 22 in 2019, then declined through the early 2020s, falling from 21 in 2021 to 5 in 2024 — a -76% drop over that three-year window. 2025 and 2026 figures are still incomplete due to the roughly 18-month gap between filing and publication, so they should not be read as a continued decline.
- 1IDEXX LABORATORIES INC33
- 2ABBOTT POINT OF CARE INC21
- 3BAYER CORP19
- 4ALIFAX18
- 5COULTER ELECTRONICS INC14
See the full hematology analyzer technology analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about hematology analyzer patents
Who are the leading patent holders in hematology analyzer technology?
The dataset ranks 44 companies by patent family count, and the field is concentrated: the leading assignee holds 33 of the 191 records in scope, well ahead of the fifth-ranked holder at 14. The top 5 assignees together account for 55.0% of all records, and the top 10 account for 82.7%. This means freedom-to-operate work in this space should prioritise checking the claim scope of a short list of established holders before broader searching.
Is hematology analyzer patent filing growing or slowing down?
Filing activity peaked in 2019 at 22 records and has since declined, falling from 21 filings in 2021 to 5 in 2024 — a drop of 76% over that three-year span. Figures for 2025 and 2026 are still incomplete because patent publication typically lags filing by about 18 months, so the most recent years should not yet be read as continuing the decline. Taken together, the pattern suggests core filing activity cooled after an early-2020s peak rather than that the technology is being abandoned.
What technology areas dominate hematology analyzer patents?
Material analysis and testing (IPC class G01N) dominates, covering 81.7% of the 191 records in scope, reflecting the centrality of impedance counting, optical and flow-based measurement methods. Healthcare informatics (G16H, 11.5%) and enzyme/DNA-based measurement (C12Q, 9.4%) form smaller but distinct clusters. Because a single record can carry multiple IPC classes, these percentages add up to more than 100%, and the smaller categories should be read as adjacent overlaps rather than separate sub-markets.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Hematology Analyzer Technology covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.